Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...
Fintel on MSN1d
Leerink Partners Downgrades Accolade (ACCD)Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...
Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...
Hosted on MSN3d
Leerink Partners Upgrades Align Technology (ALGN)Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...
NEWPORT BEACH, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- via IBN -- Roth Capital Partners, LLC (“ROTH”), announced today the ...
Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...
Stock analysts at Leerink Partnrs decreased their Q4 2025 earnings per share (EPS) estimates for Illumina in a note issued to ...
Align Technology upgraded by Leerink Partners with a $280 price target, citing growth potential, stock buyback plans, and ...
Equities researchers at Leerink Partnrs lifted their Q1 2025 earnings estimates for Illumina in a report released on Tuesday, ...
On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...
Shares of Castle Biosciences (NASDAQ: CSTL) tumbled 9% after Novitas, a regional Medicare contractor, finalized its decision not to cover one of the company's cancer tests. The Novitas Medicare ...
Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback